Table 6 Prognostic impact of serum angiogenic factors
From: Association of angiogenic factors with prognosis in esophageal cancer
Serum factor | Median | n | % | Median survival (IQR) | 95% CI | 3-Y-S (%) | p value | |
|---|---|---|---|---|---|---|---|---|
G-CSF | 35,7 | ≤ Median | 41 | 55,4% | 23,0 (12,8;*) | 12,8 - 33,2 | 40,6% | p = 0,669 |
> Median | 32 | 43,2% | 30,6 (16,0;*) | 16,2 - 45,0 | 43,5% | |||
PECAM-1 | 3243,5 | < Median | 37 | 50,0% | 29,1 (12,8;*) | 17,1 - 41,1 | 44,5% | p = 0,994 |
> Median | 37 | 50,0% | 28,5 (17,0;*) | 12,3 - 44,7 | 40,8% | |||
HGF | 979,7 | ≤ Median | 37 | 50,0% | 30,6 (12,8;*) | 12,9 - 48,3 | 43,0% | p = 0,871 |
> Median | 36 | 48,6% | 28,5 (13,7;*) | 15,7 - 41,3 | 41,1% | |||
VEGF | 37,1 | < Median | 36 | 48,6% | 23,0 (12,3;*) | 12,9 - 33,1 | 39,8% | p = 0,590 |
> Median | 36 | 48,6% | 33,7 (16,0;*) | 14,8 - 52,6 | 44,3% | |||
Leptin | 1492,7 | ≤ Median | 37 | 50,0% | 30,6 (14,0;*) | 16,5 - 44,7 | 43,5% | p = 0,800 |
> Median | 36 | 48,6% | 28,5 (11,6;*) | 10,0 - 47,0 | 41,6% | |||
PDGF-BB | 1275,1 | < Median | 37 | 50,0% | 23,8 (12,3;*) | 14,3 - 33,3 | 39,6% | p = 0,396 |
> Median | 37 | 50,0% | 36,7 (18,8;*) | - | 46,2% | |||
Angiopoietin-2 | 867,0 | ≤ Median | 37 | 50,0% | 29,1 (16,0;*) | 18,8 - 39,4 | 44,7% | p = 0,606 |
> Median | 36 | 48,6% | 28,5 (11,6;*) | 11,2 - 45,8 | 39,7% | |||
Follistatin | 200,37 | < Median | 37 | 50,0% | 30,6 (16,0;*) | - | 47,4% | p = 0,416 |
> Median | 37 | 50,0% | 23,8 (12,8;*) | 7,1 - 40,5 | 38,3% | |||
IL-8 | 11,86 | < Median | 37 | 50,0% | n.r. | - | 51,5% | p = 0,143 |
> Median | 37 | 50,0% | 21,7 (12,3;*) | 17,3 - 26,1 | 32,6% | |||
Ang-2/VEGF-Ratio | 21,9 | < Median | 36 | 48,6% | 33,7 (19,1;*) | 14,9 - 52,5 | 44,3% | p = 0,379 |
> Median | 36 | 48,6% | 23,0 (11;*) | 11,6 - 34,4 | 39,0% |